About Us
UniPharma
Advancing Healthcare with Excellence
Founded in 1998, UniPharma Co., Ltd. is committed to delivering the best medical solutions through cutting-edge expertise and unwavering dedication. Our vision is to be a leader in providing optimal healthcare choices, while our mission is to place patients at the center of everything we do, offering premium medical diagnostics, pharmaceuticals, medical devices, and treatment solutions. We uphold five core values—Professionalism, Passion, Integrity, Compassion, and Responsibility—which guide our pursuit of excellence.
As a trusted marketing and distribution partner for globally renowned pharmaceutical companies, we specialize in medical diagnostic reagents, pharmaceuticals, and medical devices. Our diagnostic solutions cover cancer and disease detection, with a particular focus on six key medical fields: colorectal surgery, obstetrics and gynecology, orthopedics, neurology, anesthesiology, and cardiology. Our clientele includes leading medical centers, regional hospitals, local hospitals, and clinics, ensuring broad accessibility to innovative and high-quality healthcare solutions.
Company Profile
A Fully Integrated Leader in Healthcare Innovation
UniPharma is recognized as a leading enterprise with a comprehensive organizational structure and a team of highly skilled professionals. Our operations span new product evaluation, market analysis, business development, international expansion, import/export, regulatory affairs, clinical research, marketing, sales, finance, warehousing and logistics, auditing, and legal affairs. This robust infrastructure enables us to be one of the few pharmaceutical companies in Taiwan capable of offering vertically integrated core competencies across R&D, clinical trials, and commercial operations.
As a comprehensive R&D-driven company, we maintain full control over our products and are continuously engaged in innovative product development. We collaborate with a team of scientific advisors and research institutions, applying the latest technologies to enhance Onko-Sure DR-70, with the goal of developing a second-generation product. In parallel, we are planning the development of a third-generation combination assay that integrates Onko-Sure DR-70 with additional tumor markers. These advanced innovations will be protected by exclusive patents, ensuring proprietary rights and market exclusivity.
Future Plan
Expanding Frontiers in Medicine and Regenerative Healthcare
UniPharma is advancing simultaneously in three key areas: pharmaceuticals, medical devices, and medical technology services. We are also actively expanding into the field of regenerative medicine, aiming to provide the highest quality diagnostics, pharmaceuticals, medical devices, and treatment solutions for both patients and animals. Our future development strategy will focus on marketing expansion and international collaborations to broaden our product portfolio and drive revenue growth.
We’re pioneering to integrate NAVIRFA radiofrequency ablation (RFA) therapy with dendritic cell (DC) immunotherapy for the treatment of liver cancer. The goal of dendritic cell therapy is to trigger tumor-specific immune responses by loading tumor antigens onto dendritic cells. This combination therapy significantly streamlines antigen preparation processes, reduces associated risks, and enhances treatment success rates.
Also, we‘re dedicated to developing innovative medical solutions, including DR-70 2.0, offering enhanced specificity and sensitivity in cancer diagnostics; and exosome-based biotech skincare and cosmetic products, leveraging advanced biotechnology for skincare applications.
We remain committed to continuous product innovation and operational excellence, ensuring the development of more effective treatment strategies to meet diverse market demands. Additionally, we uphold our core values by delivering sustained returns to investors, fostering a supportive workplace for employees, and contributing to the advancement of healthcare..
Vision
Advancing Precision Cancer Care and Corporate Responsibility
In the coming years, we well aims to establish a comprehensive, tumor-centered cancer management system, integrating cancer diagnostics, tumor ablation therapies, and blood concentration monitoring of anticancer drugs. This initiative will enhance clinical cancer services and patient treatment, offering more precise and personalized medical solutions.
Recognizing that cancer detection, treatment, and therapeutic efficacy assessment are just as critical as oncology drug development, the Board of Directors resolved in 2015 to initiate an internal audit and compliance review. In 2016, we obtained an unqualified opinion from an independent auditor and received approval for our public issuance, securing the stock code 6621. In 2017, UniPharma successfully debuted on the emerging stock market.
With our public listing, we embrace a heightened corporate social responsibility and a stronger commitment to addressing clinical needs. This responsibility extends not only to society but also to our employees. We are dedicated to fostering a healthy and supportive work environment, enabling our team to pursue their mission with passion and dedication in serving the greater community.
Looking ahead, we are prepared to tackle greater challenges, undertaking the development of next-generation pharmaceuticals, advanced medical technologies, cutting-edge medical devices, and innovative diagnostic solutions. With an unwavering commitment to innovation and excellence, we strive to expand our impact on global healthcare.
Partners
Our Business Partnership
PharmiGENE
Specializing in the research and development of pharmacogenomics and provide the tech of personalized medicine.
Genovate Biotechnology
Integrate advanced technologies and talents from domestic and international sources for the research and development of new drugs.
Baxter
The products and therapies can be found throughout hospitals and clinics – from the ER to the OR, from the pharmacy to the ICU – as well as advancing patients’ care in their homes.
Memorabilia
Annual Chronicle
UniPharma MB Lab. reinstates TAF 17025 accreditation.
● Audit by TFDA and completed the extension of the PIC/S GDP transportation license.
● General Manager Lin Liang-Guang was honorably retired, and Dr. Wang Yu-Shan is assigned as new General Manager.
● UniPharma MB Lab. terminated TAF 17025 certification temporarily.
● Signed a contract with Baxter to be the general distributor of coagulation surgical sealants in Taiwan.
UniPharma MB Lab. has been audited by TAF and complies with ISO 17025:2017 standards.
Audit by SGS and complies with ISO 13485:2016 standard.
● Merger of Jianru Pharmaceutical Co., Ltd. into a branch.
● Capital was expanded to 100 million.
● Formal listing on the OTC market.
● Recognized and certified by TFDA as a PIC/S GDP-compliant pharmaceutical company.
● MB Lab. been audited by TAF and complies with ISO 17025:2005 standard.
● Audited by SGS and complies with ISO 13485:2003 standard.
● Established a medical laboratory and will soon offer next-generation neuromedical biomarkers and anticancer drug blood concentration testing services.
● Obtained public offering approval, stock code 6621.
● Award a Outstanding GDP(Drug Administration; GDP) Supplier in 2015 from TFDA.
● Certificated and audited by TRACE anti bribery Compliance Solutions in the U.S.
● Capital was expanded to 200 million.
● To accommodate business expansion, the Board of Directors resolved during the Q4 2013 meeting to establish a new office in Neihu District, integrating the pharmaceutical warehouse and planning for a future medical laboratory. Additionally, increased the capital to 170 million.
● Received the approval to develope Onko-Sure DR-70 tumor marker in domestic.
● Signed a contract with EpiGene to be the sole distribution of Cervi-M Methylation Detection Kits for Cervical Cancer in Taiwan.
Signed a technology transfer agreement with AMDL Inc. to transfer the manufacturing of Onko-Sure DR-70 tumor marker product to Uni Pharma in Taiwan and exclusively supply it to the entire Asian market (including China, Japan, Australia, New Zealand, ASEAN countries, India and Turkey). Uni Pharma was transformed into a regional development company.
Signed a contract with Baxter for the sole distributor of anti-sticking solution products in Taiwan.
Signed an exclusive contract with AMDL Diagnostic Inc. in Taiwan for Onko-Sure DR-70 tumor marker products.
Signed a joint R&D contract with Raptor Therapeutics Inc. of the United States for the R&D, marketing and global OEM manufacturing of phase II b Convivia drug by Uni Pharma.
Represented 3 River Pharmaceuticals in the U.S. for long-acting Amphotericin (Amphocil inj.) Systemic fungal infection treatment.
● Authorized distributor of SAM Medical Products (USA) and various emergency and critical care medical devices, including Celox hemostatic powder. Successfully completed multiple medical device registration approvals and obtained regulatory licenses.
● Increased capital to 100 million.
● Merged with Xuanhao Pharmaceutical Co., Ltd., Uni Pharma as the surviving company.
● Mr. Yang Chaotang is the chairman of the board.
Signed an exclusive agency contract with Vitrolife in Sweden for lung transplant preservation solution in Taiwan.
Restructuring into a company limited by shares, with the same amount of capital.
● Signed an exclusive agency contract with Biogenidec, the third largest biotechnology company in the United States, in Taiwan.
● Plan the first biologic drug for clinical trials.
● Signed a distribution contract with 3M (Minnesota Mining Co.) Pharmaceutical Division.
● Increased capital to 22 million.
● Relocated to Zhongshan District.
● Increased capital to 18 million.
● Signed a cooperative R&D contract with Genya Biotechnology.
Uni Pharma Co., Ltd. was established in Taichung City. The capital amount is NT$200,000.